Welcome to our dedicated page for Aytu Biopharma news (Ticker: AYTU), a resource for investors and traders seeking the latest updates and insights on Aytu Biopharma stock.
Aytu BioPharma Inc (AYTU) delivers innovative therapeutics addressing critical needs in urology and neurobehavioral health. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's prescription drug developments, regulatory milestones, and strategic initiatives.
Access timely announcements including FDA approvals, clinical trial results, financial disclosures, and partnership agreements. Our curated collection ensures you stay informed about AYTU's advancements in prostate cancer diagnostics, ADHD treatments, and operational efficiency programs.
Key updates cover prescription drug pipeline progress, market expansion efforts, and expert analyses of corporate developments. Bookmark this page for direct access to primary source materials and objective reporting on Aytu BioPharma's position in the specialty pharmaceuticals sector.
Aytu BioPharma (NASDAQ:AYTU) has announced its participation in the upcoming Planet MicroCap Showcase: VEGAS 2025. The presentation is scheduled for Wednesday, April 23, 2025, at 1:30 PM Pacific time (4:30 PM Eastern) at Track 3 - Chablis in the Paris Hotel & Casino, Las Vegas.
CEO Josh Disbrow will lead the presentation and conduct a Q&A session. The event will be available via webcast, and the company will also hold one-on-one meetings with interested parties on April 24, 2025, at the conference venue. Investors interested in scheduling 1x1 meetings can coordinate through their Planet MicroCap representative or contact the company's investor relations team.
Aytu BioPharma (AYTU) reported fiscal Q2 2025 results with net income of $0.8 million and Adjusted EBITDA of $1.3 million. The company's Pediatric Portfolio showed strong performance with an 86% sequential increase in net revenue to $2.4 million, while the ADHD Portfolio revenue increased 16% sequentially to $13.8 million (adjusted for one-time effects).
Total net revenue was $16.2 million, with both portfolios showing the first quarterly sequential prescription growth since late-2022. The company maintained a strong cash position of $20.4 million as of December 31, 2024. Gross profit was $10.8 million (66% of net revenue), down from 78% in the previous year due to temporary manufacturing transition costs.
The company completed its strategic restructuring, including the divestiture of its Consumer Health business and closure of its Texas manufacturing facility, expecting at least $2.0 million in additional annual cost savings.
Aytu BioPharma (NASDAQ:AYTU) has announced it will release its fiscal 2025 second quarter operational and financial results on February 12, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern time, featuring a results review and Q&A session.
Investors can join the conference call by dialing (888) 506-0062 (US) or +1 (973) 528-0011 (international) using access code 583044. The webcast will be available live and archived at the company's investor relations website. A replay will be accessible until February 26, 2025.
Aytu BioPharma (AYTU) has announced its participation in the upcoming Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025. CEO Josh Disbrow will engage in a webcasted fireside chat at 10:00 a.m. Eastern Time during the virtual event.
The presentation will focus on the company's 2025 strategic plans, highlighting their successful realignment towards a profitable prescription pharmaceutical business. Disbrow will discuss how the streamlined organization is positioned to grow its commercialized prescription therapeutics while improving cash flow and profitability.
Key discussion points will include RxConnect, Aytu's proprietary patient access program, which facilitates affordable and hassle-free access to Aytu Rx products. The program's capability to integrate additional in-licensed or acquired products, which the company is actively pursuing, will also be addressed.
Aytu BioPharma (NASDAQ:AYTU) has announced a settlement notification regarding a derivative action lawsuit (Witmer v. Armistice Capital ). The settlement involves D&O Defendants Joshua Disbrow, Gary Cantrell, John Donofrio, Jr., Carl Dockery, and Ketan B. Mehta.
A settlement hearing is scheduled for January 13, 2025, at 3:15 p.m. at the Court of Chancery of Delaware to determine if the settlement terms are fair and reasonable. Current AYTU shareholders as of October 9, 2024 (Record Date) may have rights regarding the proposed settlement and can obtain detailed information from the company's website or by contacting Morris Kandinov LLP.
Shareholders who don't object to the settlement need not take any action or appear at the hearing. Those who don't object or appear will be bound by the Court's final judgment.
Aytu BioPharma (Nasdaq:AYTU) has been ranked 380th on the 2024 Deloitte Technology Fast 500™, marking its fourth consecutive year on the list of North America's fastest-growing companies. The company reported significant financial improvements in fiscal 2024, with consolidated adjusted EBITDA reaching $9.2 million, a 162% increase from $3.5 million in fiscal 2023. Management expects continued growth in Rx Segment net revenue and adjusted EBITDA for fiscal 2025, focusing on driving prescription demand and improving portfolio coverage and patient access.
Aytu BioPharma reported positive financial results for Q1 fiscal 2025, marking its first-ever quarterly net income of $1.5 million. Net revenue was $16.6 million, with ADHD Portfolio revenue up 1% to $15.3 million and Pediatric Portfolio revenue showing a 54% sequential increase to $1.3 million. The company maintained a strong gross profit margin of 72% and reported Adjusted EBITDA of $1.9 million. Cash position remained stable at $20.1 million. The company implemented organizational changes expected to reduce operating expenses by at least $2.0 million annually, including executive changes and the promotion of Ryan Selhorn to CFO.
Aytu BioPharma (Nasdaq:AYTU) has scheduled its fiscal 2025 first quarter operational and financial results announcement for November 13, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern time on the same day, including a Q&A session. Interested parties can join via phone using the access code 428941 or watch the webcast live through the company's investor relations website. A replay will be available until November 27, 2024.
Aytu BioPharma (Nasdaq: AYTU) announced its participation in the 2024 Maxim Healthcare Virtual Summit. CEO Josh Disbrow will engage in a fireside chat on Wednesday, October 16, 2024, at 2:00 p.m. Eastern time. The event is virtual, and interested parties can sign up to view the presentation through a provided link.
Following the event, one-on-one investor meetings will be available upon request. Investors can arrange these meetings by contacting their Maxim representative or Aytu's investor relations group at aytu@lythampartners.com.
Aytu BioPharma is a pharmaceutical company that focuses on commercializing novel therapeutics. This summit participation provides an opportunity for investors to gain insights into the company's operations and future plans.
Aytu BioPharma and Lupin Pharma Canada have signed an exclusive agreement to commercialize Adzenys XR-ODT and Cotempla XR-ODT in Canada for ADHD treatment. These products will be the only orally disintegrating, extended-release tablets for ADHD in Canada once approved by Health Canada. Adzenys XR-ODT is bioequivalent to Adderall XR, while Cotempla XR-ODT is the only extended-release orally disintegrating methylphenidate tablet.
Aytu's ADHD portfolio has seen a 16.5% increase in prescriptions over the past two years. The Canadian ADHD stimulant market recorded 4.5 million units and $1.1 Billion CAD in gross sales in 2023. Lupin will seek regulatory approvals for both products, expected within the next 18 to 24 months.
